Search clinical trials for: AZD5213

Total 100 results

AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
AstraZeneca

Completed

A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

Mild Cognitive Impairment | Mild Alzheimer's Disease

United States
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

Tourette Syndrome

United States
AstraZeneca

Completed

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Healthy

United States
AstraZeneca

Completed

Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Tolerability

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration

Brain Distribution of [11C]AZ12807110 and AZD5213

Sweden
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

Dilated Cardiomyopathy

United States
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
AstraZeneca
Parexel

Completed

A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers

Coronary Artery Disease (CAD)

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Hypercholesterolemia

United States
AstraZeneca

Completed

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability (OAK)

Safety and Tolerability, | Advanced Solid Malignancy, | Pharmacokinetics, Pharmacodynamics, | Tumour Response,

United Kingdom, Netherlands
AstraZeneca
Parexel

Terminated

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

End Stage Renal Disease

Poland
AstraZeneca
Parexel

Completed

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

Chronic Kidney Disease

United Kingdom
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
AstraZeneca

Completed

An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

Healthy

Sweden
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers

Coronary Artery Disease

United Kingdom
AstraZeneca
Quintiles, Inc.

Completed

To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers

Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years. | Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80

United Kingdom
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

Healthy

Japan
AstraZeneca

Completed

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (AZD3293hADME)

Healthy Volunteers | Mass Balance Study

United States
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Alzheimer's Disease

United States, Spain, Australia, Belgium, Korea, Republic of, United Kingdom, Germany, Poland, Canada, Japan, Romania, France, Puerto Rico, Hungary
AstraZeneca

Completed

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (BA)

Healthy Volunteers | Pharmacologic Action

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. (PYRUS)

Metastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.

United Kingdom, United States
National University Heart Centre, Singapore
AstraZeneca

Recruiting

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE (PASSIVATE)

Acute Coronary Syndrome

Australia, New Zealand, Singapore
AstraZeneca

Completed

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD). (FLAVOUR)

Coronary Artery Disease

Denmark, Finland, Sweden
AstraZeneca

Completed

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

Healthy

United Kingdom
AstraZeneca
Eli Lilly and Company

Terminated

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH)

Alzheimer´s Disease

United States, Spain, Belgium, Australia, Hungary, Korea, Republic of, Canada, Germany, Japan, Romania, France, Poland, United Kingdom, Puerto Rico, Italy
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Unknown

A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)

Adenocarcinoma of the Prostate

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
AstraZeneca
Parexel

Completed

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Prostate Cancer

Spain, United States
AstraZeneca
Parexel

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

Dyslipidemia

United States
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK-ALZ)

Alzheimer's Disease

United States, Spain, Korea, Republic of, Italy, Portugal, China, Taiwan, Czechia, Japan, Poland, France, Netherlands, United Kingdom, Germany, Russian Federation, Canada, Mexico, Denmark
AstraZeneca

Completed

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Bioavailability and AUC

United Kingdom
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
University of Nottingham
AstraZeneca; Cancer Research UK; National Cancer Research Network

Completed

AKT Inhibitor in Oestrogen Positive Breast Cancer (STAKT)

Invasive Breast Cancer

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia (SOLANO)

Hyperlipidaemia

Denmark, Netherlands, Spain, Czechia, United States, Slovakia, Hungary, Poland
University of Michigan Rogel Cancer Center

Terminated

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
AstraZeneca

Completed

AZD5423 Multiple Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Completed

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

Healthy Elderly Volunteers | Healthy Young Volunteers

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...

Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma | Recurrent Meningioma | NF2 Gene Mutation

United States
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
AstraZeneca

Completed

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor

United Kingdom, United States
AstraZeneca
Eli Lilly and Company

Completed

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Healthy

United States
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
AstraZeneca

Completed

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers

Japan
AstraZeneca

Completed

AZD5423 Single Ascending Dose Study

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects

Healthy

Japan

3

Subscribe